Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.
Shankar
S
S
Radiology Department, University of Massachusetts Medical Center, Worcester, Massachusetts 01655, USA.
Dundamadappa
S K
SK
Karam
A R
AR
Stay
R M
RM
van Sonnenberg
E
E
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D003287:Contrast Media; D018450:Disease Progression; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010879:Piperazines / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D003287:Contrast Media; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate